Targeting telomerase for cancer therapeutics

J. W. Shay; W. N. Keith

doi:10.1038/sj.bjc.6604209

Targeting telomerase for cancer therapeutics

J. W. Shay, W. N. Keith

Research output: Contribution to journal › Short survey › peer-review

143 Scopus citations

Abstract

One of the hallmarks of advanced malignancies is continuous cell growth and this almost universally correlates with the reactivation of telomerase. Although there is still much we do not understand about the regulation of telomerase, it remains a very attractive and novel target for cancer therapeutics. Several clinical trials have been initiated, and in this review we highlight some of the most promising approaches and conclude by speculating on the role of telomerase in cancer stem cells.

Original language	English (US)
Pages (from-to)	677-683
Number of pages	7
Journal	British journal of cancer
Volume	98
Issue number	4
DOIs	https://doi.org/10.1038/sj.bjc.6604209
State	Published - Feb 26 2008

Keywords

Ageing
Targeted therapeutics
Telomeres

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1038/sj.bjc.6604209

Cite this

@article{38d0f605cee24024aff6b06f9b82f5d0,

title = "Targeting telomerase for cancer therapeutics",

abstract = "One of the hallmarks of advanced malignancies is continuous cell growth and this almost universally correlates with the reactivation of telomerase. Although there is still much we do not understand about the regulation of telomerase, it remains a very attractive and novel target for cancer therapeutics. Several clinical trials have been initiated, and in this review we highlight some of the most promising approaches and conclude by speculating on the role of telomerase in cancer stem cells.",

keywords = "Ageing, Targeted therapeutics, Telomeres",

author = "Shay, {J. W.} and Keith, {W. N.}",

note = "Funding Information: We thank Angela Diehl for illustrations and Professor TRJ Evans for valuable discussions. Research support by Cancer Research UK, University of Glasgow (WNK), European Community grant LSHC-CT-2004-502943 (to WNK), Lung Cancer SPORE P50 CA75907, NSCOR NNJ05HD36G and the Ted Nash Foundation (to JWS) is acknowledged.",

year = "2008",

month = feb,

day = "26",

doi = "10.1038/sj.bjc.6604209",

language = "English (US)",

volume = "98",

pages = "677--683",

journal = "British journal of cancer",

issn = "0007-0920",

publisher = "Nature Publishing Group",

number = "4",

}

TY - JOUR

T1 - Targeting telomerase for cancer therapeutics

AU - Shay, J. W.

AU - Keith, W. N.

N1 - Funding Information: We thank Angela Diehl for illustrations and Professor TRJ Evans for valuable discussions. Research support by Cancer Research UK, University of Glasgow (WNK), European Community grant LSHC-CT-2004-502943 (to WNK), Lung Cancer SPORE P50 CA75907, NSCOR NNJ05HD36G and the Ted Nash Foundation (to JWS) is acknowledged.

PY - 2008/2/26

Y1 - 2008/2/26

N2 - One of the hallmarks of advanced malignancies is continuous cell growth and this almost universally correlates with the reactivation of telomerase. Although there is still much we do not understand about the regulation of telomerase, it remains a very attractive and novel target for cancer therapeutics. Several clinical trials have been initiated, and in this review we highlight some of the most promising approaches and conclude by speculating on the role of telomerase in cancer stem cells.

AB - One of the hallmarks of advanced malignancies is continuous cell growth and this almost universally correlates with the reactivation of telomerase. Although there is still much we do not understand about the regulation of telomerase, it remains a very attractive and novel target for cancer therapeutics. Several clinical trials have been initiated, and in this review we highlight some of the most promising approaches and conclude by speculating on the role of telomerase in cancer stem cells.

KW - Ageing

KW - Targeted therapeutics

KW - Telomeres

UR - http://www.scopus.com/inward/record.url?scp=39449092745&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39449092745&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6604209

DO - 10.1038/sj.bjc.6604209

M3 - Short survey

C2 - 18231105

AN - SCOPUS:39449092745

SN - 0007-0920

VL - 98

SP - 677

EP - 683

JO - British journal of cancer

JF - British journal of cancer

IS - 4

ER -

Targeting telomerase for cancer therapeutics

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this